TMB and PD‐L1 expression levels on tumor cells guide decisions for ICI‐based therapies.[28] In the absence of driver mutations, alternative treatment strategies are needed.[50, 51, 52] The introduction of ICIs has altered the treatment landscape, offering durable responses for a subset of patients without driver alterations. The gene discussed is CD274; the disease is neoplasm.